These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 38189866

  • 1. A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat.
    Locatelli F, Ravera M, Esposito C, Grandaliano G, Gesualdo L, Minutolo R.
    J Nephrol; 2024 May; 37(4):1107-1119. PubMed ID: 38189866
    [Abstract] [Full Text] [Related]

  • 2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U, Signore PE, Walkinshaw G, Seeley TW, Brenner MC, Wang Q, Guo G, Arend MP, Flippin LA, Chow FA, Gervasi DC, Kjaergaard CH, Langsetmo I, Guenzler V, Liu DY, Klaus SJ, Lin A, Neff TB.
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [Abstract] [Full Text] [Related]

  • 3. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
    Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE.
    J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
    [Abstract] [Full Text] [Related]

  • 4. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T, Yamaguchi Y, Otsuka T, Reusch M.
    Nephron; 2020 Mar; 144(8):372-382. PubMed ID: 32580188
    [Abstract] [Full Text] [Related]

  • 5. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
    Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KP, Neff TB.
    Clin J Am Soc Nephrol; 2016 Jun 06; 11(6):982-991. PubMed ID: 27094610
    [Abstract] [Full Text] [Related]

  • 6. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
    Sanghani NS, Haase VH.
    Adv Chronic Kidney Dis; 2019 Jul 06; 26(4):253-266. PubMed ID: 31477256
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP.
    N Engl J Med; 2019 Sep 12; 381(11):1001-1010. PubMed ID: 31340089
    [Abstract] [Full Text] [Related]

  • 11. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, Jiang G, Lin H, Zhang X, Zuo L, He Q, Fu P, Li X, Ni D, Hemmerich S, Liu C, Szczech L, Besarab A, Neff TB, Peony Yu KH, Valone FH.
    Nephrol Dial Transplant; 2017 Aug 01; 32(8):1373-1386. PubMed ID: 28371815
    [Abstract] [Full Text] [Related]

  • 12. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, Yu KP.
    J Clin Pharmacol; 2020 Nov 01; 60(11):1432-1440. PubMed ID: 32603526
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L, Locatelli F.
    Expert Opin Investig Drugs; 2018 Jan 01; 27(1):125-133. PubMed ID: 29254377
    [Abstract] [Full Text] [Related]

  • 15. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X, Zuo L, Luo L, Wang J, Zhao MH, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP.
    N Engl J Med; 2019 Sep 12; 381(11):1011-1022. PubMed ID: 31340116
    [Abstract] [Full Text] [Related]

  • 16. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A.
    Eur J Pharmacol; 2021 Dec 05; 912():174583. PubMed ID: 34678238
    [Abstract] [Full Text] [Related]

  • 17. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
    Kurata Y, Tanaka T, Nangaku M.
    Expert Opin Pharmacother; 2022 Jan 05; 23(1):19-28. PubMed ID: 34686069
    [Abstract] [Full Text] [Related]

  • 18. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis.
    Yang J, Xing J, Zhu X, Xie X, Wang L, Zhang X.
    Front Endocrinol (Lausanne); 2023 Jan 05; 14():1131516. PubMed ID: 37008953
    [Abstract] [Full Text] [Related]

  • 19. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
    Kile M, Sudchada P.
    Int Urol Nephrol; 2021 Feb 05; 53(2):283-290. PubMed ID: 32770437
    [Abstract] [Full Text] [Related]

  • 20. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB.
    Am J Kidney Dis; 2016 Jun 05; 67(6):912-24. PubMed ID: 26846333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.